Cocrystal Pharma, Inc.
COCPAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jun 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 22, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jan 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 2, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jan 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Nov 7, 2022 |
| HC Wainwright & Co. | maintain | Buy | Nov 12, 2020 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.17| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.23 | $-0.17 | $100.0K | $50.0K |
| May 15, 2026 | $-0.17 | $-0.15 | $100.0K | $225.0K |
| Mar 31, 2026 | $-0.17 | $-0.18 | — | — |
| Nov 14, 2025 | $-0.19 | $-0.22 | — | — |
| Aug 14, 2025 | $-0.20 | $-0.30 | — | — |
| May 15, 2025 | $-0.23 | $-0.52 | — | — |
| Mar 31, 2025 | $-0.32 | $-0.55 | — | — |
| Nov 13, 2024 | $-0.49 | $-0.57 | — | — |
News
Cocrystal Pharma (NASDAQ: COCP - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Volatility and Risk Cocrystal Pharma has a
No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash.
BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.